Company Profile

SUN PHARMACEUTICAL INDUSTRIES LTD.

NSE : SUNPHARMABSE : 524715ISIN CODE : INE044A01036Industry : Pharmaceuticals & DrugsHouse : Sun Pharma
BSE414.75-2.3 (-0.55 % )
PREV CLOSE (Rs.) 417.05
OPEN PRICE (Rs.) 419.85
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 414.75 (632 )
VOLUME 312082
TODAY'S LOW / HIGH (Rs.)410.10 424.00
52 WK LOW / HIGH (Rs.)350.4 678.8
NSE414.70 -2.45 (-0.59 % )
PREV CLOSE(Rs.) 417.15
OPEN PRICE (Rs.) 419.40
BID PRICE (QTY) 414.70 (8702 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 6536156
TODAY'S LOW / HIGH(Rs.) 410.00 421.40
52 WK LOW / HIGH (Rs.)344.55 679.3

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.66
TTM EPS (Rs.) 3.69
P/E Ratio 112.27
Book Value (Rs.) 98.39
Face Value (Rs.) 1
MCap (Rs. in Mn) 995124.18
Price/Earning (TTM) 70.55
Price/Sales (TTM) 10.27
Price/Book (MRQ) 4.22
PAT Margin (%) 6.58
ROCE (%) 4.31
Incorporation Year : 1993

Management Info :

Israel Makov - Chairman Dilip S Shanghvi - Managing Director

Registered Office :

Address : Sun Pharma Advanced Research Centre (S P A R C),Tandalja,,
Vadodara,
Gujarat-390020

Phone : 0265- 5515500 / 5515600 / 5515700

Website : www.sunpharma.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
17Aug08-17-2019$Sun Pharma, CMS ink licensing agreement for generic products in Mainland China Sun Pharma, CMS ink licensin

Sun Pharmaceutical Industries’ one of wholly owned subsidiaries has granted an exclusive license to a subsidiary of China Medical System Holdings (CMS) to develop and commercialize seven generic products in Mainland China. The collaboration with CMS now covers eight generic products including the seven products referred above. The total addressable market size for all these eight products is about $1 billion (as per recent IQVIA data) in Mainland China.

The initial term of the agreement shall be 20 years from the first commercial sale of the respective products in Mainland China and may be extended for additional three years' as per mutual agreement of the two parties.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharmaceutical Industries’ one of wholly owned subsidiari..
14Aug08-14-2019$Sun Pharma enters into licensing agreement with CSIR-IICT Sun Pharma enters into licen

Sun Pharmaceutical Industries has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma’s specialty focus areas.

Under the terms of the license agreement, the company gets exclusive global license for the said patents and any other future patents covered in the agreement. The company will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totaling up to Rs 2.40 billion, plus royalties on net sales from commercialization of the products developed using these patents. The company will be responsible for development, regulatory filings, manufacturing and commercialization of these potential products.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharmaceutical Industries has entered into a global licensi..
14Aug08-14-2019$CONCOR, Infosys and Wipro to see some action today CONCOR, Infosys and Wipro to

Container Corporation of India (CONCOR) and Indian Railways have joined hands to commence Container Train operations from Suranussi, located near Jalandhar in Firozpur Division of Northern Railway. This new facility shall give impetus to transportation of Domestic and EXIM cargo in containers from the catchment areas of Jalandhar, Hoshiarpur, Kapurthala and Amritsar.

Infosys has been selected by Toyota Material Handling North America (TMHNA) for a cloud based IoT telematics product implementation along with application support and development for its SAP Platform. As the development partner for TMHNA Global Telematics Solution (GTS), an industry leading cloud-based IoT offering, the company will enable remote monitoring and diagnostic capabilities including vehicle access control, system maintenance, condition sensing and location tracking.

Wipro has launched three edge artificial intelligence (AI) starter solutions powered by Intel Xeon Scalable processors. These starter solutions will help enterprises in the Energy & Utilities and Healthcare markets jump start their AI adoption. The company will leverage Intel's AI technology to maximize performance of the Wipro AI solutions when running on Intel Xeon Scalable processors.

Persistent Systems has completed the closing conditions related to acquisition of selected assets from Above Solutions India and its affiliates.

Sun Pharmaceutical Industries has reported a rise of 28.67% in its net profit at Rs 763.37 crore for the quarter ended June 30, 2019 as compared to Rs 593.29 crore for the same quarter in the previous year. Total income of the company increased by 9.17% at Rs 3,327.59 crore for Q1FY20 as compared Rs 3,048.03 crore for the corresponding quarter previous year.

CCL Products (India) is planning to invest $20 million during the current fiscal (FY20) to enhance capacities and infrastructure. The company will spend $12 million on the agglomeration and packaging unit in India (Chittoor plant) and $8 million in Vietnam plant capacity enhancement.

ZEE Entertainment Enterprises (ZEEL) has acquired balance 26% stake in its 74% Subsidiary, Zee Network Distribution (earlier known as Zee-Turner). Accordingly, Zee Network Distribution has now become a wholly owned subsidiary of the company on and from August 9, 2019.

Container Corporation of India (CONCOR) and Indian Railways hav..
13Aug08-13-2019$Sun Pharma reports 31% rise in Q1 consolidated net profit Sun Pharma reports 31% rise

Sun Pharmaceutical Industries has reported results for first quarter ended June 30, 2019.

The company has reported a rise of 28.67% in its net profit at Rs 763.37 crore for the quarter under review as compared to Rs 593.29 crore for the same quarter in the previous year. Total income of the company increased by 9.17% at Rs 3,327.59 crore for Q1FY20 as compared Rs 3,048.03 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 31.23% in its net profit at Rs 1,387.48 crore for the quarter under review as compared to Rs 1,057.29 crore for the same quarter in the previous year. Total income of the company increased by 15.67% at Rs 8,587.38 crore for Q1FY20 as compared Rs 7,423.92 crore for the corresponding quarter previous year.

Sun Pharmaceutical Industries has reported results for first qu..
03Aug08-03-2019$Sun Pharma discontinues operations at two clinical pharmacology units in Vadodara Sun Pharma discontinues oper

Sun Pharmaceutical Industries is discontinuing operations at two clinical pharmacology units in Vadodara (Gujarat) to bring in efficiencies in cost and processes. To ensure optimal utilisation of clinical pharmacology units (CPUs) that conduct bio-equivalence studies, the company is discontinuing operations at two centers at Tandalja and Akota in Vadodara.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharmaceutical Industries is discontinuing operations at tw..
Financials More
Rs. in Millions
QTR Jun 19 ANNUAL 19
Net Profit7633.78166
Gross Profit 7681.4 7194.5
Operating Profit 9609.730277
Net Sales 33090.1103032.1
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Astrazeneca Pharma I (BSE)
 1708.40 (1.53%)
M.Cap ( in Cr)
4271.00
Everest Organics (BSE)
 172.65 (17.45%)
M.Cap ( in Cr)
138.12
Piramal Enterprises (BSE)
 1782.55 (0.90%)
M.Cap ( in Cr)
35445.39
Ajanta Pharma (BSE)
 996.45 (1.56%)
M.Cap ( in Cr)
8694.50
Samrat Pharmachem (BSE)
 73.20 (20.00%)
M.Cap ( in Cr)
22.62
Shareholding Pattern More
FI/BANKS/INSURANCE 7.67 %
PROMOTERS 54.38 %
NON-INSTITUTION 12.71 %
MUTUAL FUNDS/UTI 10.26 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes